Say Ebola and a single image loads: the bleeding. The textbooks and the disaster movies trained an entire generation of doctors and travelers to watch for hemorrhage as the tell, the moment a bad fever becomes the thing you evacuate a hospital over. Now hold that image against the outbreak burning through the eastern Democratic Republic of the Congo, where a preliminary clinical report finds roughly 90 percent of confirmed patients arrived with no hemorrhagic signs at all. No bleeding. Just fever, vomiting, and diarrhea, the same opening act as malaria, typhoid, or a rough bout of food poisoning in a region that sees all three constantly.

People are trained to watch for one thing, and this virus mostly does another. That mismatch let the outbreak grow quietly before anyone named it, and it gets worse the deeper you look: the world spent a decade building its Ebola defenses around a different species of the virus than the one now spreading.

A different Ebola, with a different rulebook

We have seen Ebola outbreaks before, and recently. The 2014 to 2016 West Africa catastrophe and the 2018 to 2020 eastern Congo epidemic were both driven by Zaire ebolavirus, the species the world built its tools against. This one is different in a way that reaches down to the molecular level: it is Bundibugyo virus, a separate species first identified in 2007 in Uganda’s Bundibugyo District and seen only twice since, in Uganda then and in Congo in 2012. Doctors Without Borders puts its historical fatality rate at 25 to 40 percent, well below the 50-plus percent of Zaire, and that milder front end is exactly what makes it slippery. A virus that kills slower lets infected people keep moving, keep working, keep seeing relatives, before anyone realizes what they are carrying.

The DRC and Uganda both declared outbreaks of the disease on May 15, 2026, and within two days the World Health Organization had determined it a public health emergency of international concern, its highest level of alarm. The earliest clusters, the CDC’s field investigators found, turned up among health care workers, the people most likely to be standing over a patient with no idea the fever in front of them was Ebola, because the patient wasn’t bleeding.

The numbers, and how fast they moved

The growth has been fast. The CDC’s June 2 field report counted 378 confirmed cases and 63 deaths across the two countries, a case fatality rate near 17 percent. By June 14, the WHO’s regional office logged 808 confirmed cases and 192 deaths across Ituri, North Kivu, and South Kivu, with the fatality rate climbing to 23.8 percent. By June 24 the tally had reached 1,118 confirmed cases and 291 deaths in DRC, with Uganda confirming 20 of its own and two deaths; a US citizen who tested positive was medically evacuated to Germany in May, and a returning humanitarian physician became a confirmed case in France on June 24. This is already the largest Bundibugyo outbreak ever recorded, in a virus that until two months ago had infected only a few hundred people in its entire known history.

The gap a decade of “preparedness” didn’t close

After the 2014 West Africa disaster, the global health apparatus spent the better part of a decade and an enormous amount of money on Ebola readiness, and it produced real tools: two licensed vaccines and monoclonal-antibody treatments that work. Every one of them was built against the Zaire species. Against Bundibugyo, Doctors Without Borders is blunt that there is no approved vaccine and no approved treatment; the monoclonals developed for Zaire don’t neutralize it, and the experimental candidates that might have no established efficacy. Care comes down to fluids, fever control, and isolation, the same arsenal we had in 1976.

It gets worse at the diagnostic level, where the MSF teams on the ground say PCR confirmation requires virus-specific kits that are “currently available in insufficient quantities for the Bundibugyo virus.” Knowing who is infected is the first move in any outbreak, and the response is short on the one test that establishes it, which slows confirmation and contact tracing exactly when speed is everything. So the flagship preparedness investment turns out to have prepared for the last virus, not this one. That is not a knock on the scientists who built the Zaire tools, which have saved lives. It is a fair question to put to an apparatus that declared itself ready for Ebola while holding licensed tools for exactly one of the species that causes it.

What the models say happens next

The CDC’s modeling team ran the scenarios, and they are worth reading without panic and without false comfort. They estimate the spillover from an unknown animal reservoir happened back in February, giving the virus a months-long head start before anyone was watching, and they put its basic reproduction number at a median of 2.51, the range where an outbreak grows unless it is actively suppressed. The whole forecast hinges on one lever: how many sick people get isolated, and how fast. If responders isolate only about 20 percent of symptomatic cases, the majority of the simulations blow past 20,000 cases and 4,000 deaths. Push that to 70 percent, and most stay under 10,000. The CDC’s own conclusion is that without large-scale, rapid action this could become “one of the largest Ebola epidemics in history.” The math is not destiny. It is a measure of how much the response matters, and the response is currently short on tests.

The American angle, in proportion

For readers in the United States, the honest framing is neither dismissal nor dread. The CDC rates the risk to the US population as low, with moderate confidence, estimating the relative likelihood of importation at just 1.3 percent compared with other destinations, and enhanced traveler screening began May 18. American hospitals that handled imported Ebola cases in 2014 contained them without community spread, and the machinery for case identification and isolation here is real. The thing to watch is not a movie-style outbreak on US soil. It is whether the same institutions that spent a decade and a fortune declaring themselves ready can now get virus-specific tests, isolation capacity, and trained responders to the place that actually needs them, fast enough to choke this off at the source. A Bundibugyo virus that mostly doesn’t bleed was always going to be underestimated. The only question left is whether the people who promised they were ready stop underestimating it in time.

Sources

  1. MedPage Today – Hemorrhage May Be ‘Infrequent’ Feature in Latest Ebola Outbreak
  2. CDC MMWR – Notes from the Field: Outbreak of Ebola Disease Caused by Bundibugyo Virus, DRC and Uganda, May 2026
  3. CDC MMWR – Modeled Scenario Projections for the Bundibugyo Virus Outbreak, 2026
  4. CDC MMWR – Assessment of Risk to the U.S. Population, Bundibugyo Virus, 2026
  5. WHO – Disease Outbreak News: Ebola caused by Bundibugyo virus, DRC & Uganda
  6. Doctors Without Borders – Bundibugyo virus: why this Ebola disease outbreak is different
  7. WHO Regional Office for Africa – Bundibugyo virus disease outbreak situation report, data as of 14 June 2026
  8. ECDC – Ebola disease outbreak in the Democratic Republic of the Congo and Uganda